Extracorporeal Photopheresis

Medicare covers extracorporeal photopheresis for palliative treatment of skin manifestations of cutaneous T‑cell lymphoma and for acute cardiac allograft rejection and chronic graft‑versus‑host disease when disease is refractory to standard therapies. ECP for bronchiolitis obliterans syndrome after lung transplantation is covered only when provided under a clinical research study that meets the NCD's detailed Coverage with Evidence Development requirements; all other indications are non‑covered.

"Extracorporeal photopheresis (ECP) is covered as palliative treatment for skin manifestations of cutaneous T‑cell lymphoma (CTCL) that have not responded to other therapy."

Sign up to see full coverage criteria, indications, and limitations.